Judo Bio announced the company's launch and $100 million in initial financing, including seed financing and Series A. Atlas Venture founded and incubated Judo Bio with The Column Group joining the seed financing. The Series A was recently closed and co-led by Atlas Venture, TCG and Droia Ventures, with participation from Digitalis Ventures, Euclidean Capital, Alexandria Venture Investments, YK Bioventures, and other undisclosed funds.

Judo Bio has discovered a novel approach to create oligonucleotide medicines targeted to the kidney, an organ that has been challenging to access for genetic medicines. The company has completed preclinical studies successfully demonstrating receptor-mediated delivery of oligonucleotides to the kidney with proprietary ligand-siRNA conjugates that silence multiple target genes.